New developments type 1 (insulin-dependent) diabetes

Clinical Pediatrics

Volumn 39, Issue 5, 2000, Pages 257-266

  Silverstein, Janet H ^a,b   Rosenbloom, Arlan L ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Children's Medical Center of North Florida   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; AMINOGUANIDINE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; GLUCOSE; GLUCOSE OXIDASE; INSULIN; INSULIN DERIVATIVE; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; MONOCLONAL ANTIBODY CD3; NICOTINAMIDE; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ARTICLE; BLOOD GLUCOSE MONITORING; DEVICE; DIABETES CONTROL; DIABETIC MICROANGIOPATHY; DRUG DELIVERY SYSTEM; DRUG INDICATION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; PANCREAS ISLET TRANSPLANTATION;

EID: 0034073576     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/000992280003900501     Document Type: Article

References (45)

1. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulindependent diabetes mellitus. N Engl J Med. 1993;329:977-986.
2. White JR, Campbell RK, Hirsch I. Insulin analogues: new agents for improving glycemic control. Postgrad Med. 1997;101:60-70.
3. Barnett AH, Owens DR. Insulin analogues. Lancet. 1997;349:47-51.
4. Holleman F, Hoekstra JBL. Insulin lispro. N Engl J Med. 1997;337:176-183.
5. Anderson JH, Brunelle R, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Diabetes. 1997;46: 265-270.
6. Holleman F, Schmitt H, Rottiers R, et al. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. Diabetes Care. 1997;20:1827-1832.
7. Coates PA, Mukherjee S, Luzio S, et al. Pharmacokinetics of a "long-acting" human insulin analogue (HOE 901) in healthy subjects. Diabetes. 1995;44 (suppl 1) 130.
8. Owens D, Luzio S, Beck P, et al. The absorption of the insulin analogue HOE 901 from different sites in healthy subjects. Diabetes. 1997; 46(suppl I):329A.
9. Rosskamp RH, Park G. Long-acting insulin analogs. Diabetes Care 1999;22(suppl 2):B109-B113.
10. Pieber T, Eugene-Jolchine I, Derobert E. Efficacy and safety of HOE 901 in patients with Type 1 diabetes, a four-week randomized, NPH insulin-controlled trial. Diabetes. 1998;47(suppl 1):A62.
11. Rosenstock J. Park G, Zimmerman J. Efficacy and safety of HOE 901 in patients with type 1 DM: a four-week randomized NPH insulin-controlled trial. Diabetes. 1998;47(suppl 1):A92.
12. Matthews DR, Pfeiffer C. Comparative clinical trial of a new long-acting insulin (HOE 901) vs protamine insulin demonstrates less nocturnal hypoglycemia. Diabetes. 1998;47(snppl 1):A101.
13. Markussen J, Havelund S, Kurtzhals P, et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia. 1996;39:281-288.
14. Llewelyn J, Martin J, Bates P. Patient acceptability and safety of a new prefilled 3.0 ml. insulin pen in the clinical setting. Diabetes. 1998;47(suppl 1):A358.
15. Gelfand RA, Schwartz SL, Horton M, et al. Pharmacological reproducibility of inhaled human insulin pre-meal dosing in patients with type 2 diabetes mellitus (NIDDM). Diabetes. 1998; 47(suppl 1):A99.
16. Saudek CD. Novel forms of insulin delivery. Endocrinol Metab Clin North Am. 1997;26:599-610.
17. Skyler JS, Gelfand RA, Korides IA, et al. Treatment of type 1 DM with inhaled human insuln: a 3-month multicenter trial. Diabetes. 1998;47(suppl 1):A61.
18. Farkas-Hirsch R, Hirsch IB. Continuous subcutaneous insulin infusion: a review of the past and its implementation for the future. Diabetes Spectrum. 1994;7:80-84.
19. Hirsch IB. Intensive treatment of type 1 diabetes. Med Clin North Am. 1998;82:689-719.
20. Saudek CD. Novel froms of insulin delivery, Curr Ther Diabetes. 1997;26:599-619.
21. Selam JL. Management of diabetes with glucose sensors and implantable insulin pumps. From the dream of the 60s to the realities of the 90s. ASAIO J. 1997;43:137-142.
22. Klonoff DC. Noninvasive blood glucose monitoring. Diabetes Care. 1997;20:433-437.
23. Heise HM. Noninvasive monitoring of metabolites using near infrared spectroscopy: state of the art. Horm Metab Res. 1996;28:527-534.
24. Tamada J. Tierney M, Berman B, et al. In vivo studies of a noninvasive glucose monitor in subjects with diabetes. Diabetes. 1998;47(suppl 1):A62.
25. Mettenburg J. Breaking the skin barrier. JDF International Countdown, 1998:13-18.
26. Mastrototaro J, Levy R, Georges LP, et al. Clinical results from a continuous glucose sensor multicenter study. Diabetes. 1998;47(suppl 1):A61.
27. Bantle JP, Thomas W. Glucose measurement in patients with diabetes mellitus with dermal interstitial fluid. J Lab Clin Med. 1997;130:436-441.
28. Kasiske BL, Kalil KSN, Ma JA, et al. Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med. 1993;118:129-138.
29. Haussen KF. Making sense of advanced glycation end products (ACE). Int Diabetes Monitor. 1998;10:1-4.
30. Friedman EA. Advanced glycosylated end products and hyperglycemia in the pathogenesis of diabetic complications. Diabetes Care. 1999;22(suppl 2):B65-B70.
31. Airey M, Bennett C, Nicolucci A, Williams R. The efficacy of aldose reductase inhibitors in the treatment of diabetic peripheral neuropathy (Cochrane Review). In: The Cochrane Library, Issue I. Oxford: Update Software; 1999.
32. Kendall D, Robertson RP. Pancreas and islet transplantation: challenges for the twenty-first century. Endocrinol Metab Clin North Am. 1997; 26:611-630.
33. Masetti M, Inveradi L, Ranuncole A, et al. Current indications and limits of pancreatic islet transplantation in diabetic nephropathy. J Nephrol. 1997;10:245-252.
34. Alejandro R. Lehmann R, Ricordi C, et al. Long-term function (6 years) of islet allografts in Type 1 diabetes. Diabetes. 1997;46:1983-1989.
35. Hering BJ, Brendel MD, Schultz AO, et al. Newsletter No. 7. Int Islet Transplant Registry. 1996;6:1-20.
36. Atkinson MA, Maclaren NK. The pathogenesis of insulin-dependent diabetes mellitus. N Engl J Med. 1994;331:1428-1436.
37. Verge CF, Gianani R, Kawasake E, et al. Prediction of type 1 diabetes in first-degree relatives using a combination of insulin, GAD, and ICA512 bdc/IA-2 autoantibodies. Diabetes. 1996;45:926-933.
38. Riley WJ, Maclaren NK, Krischer J. et al. A prospective study of the development of diabetes in relatives of patients with insulin dependent diabetes. N Engl J Med. 1990;323: 1167-1172.
39. Wilson B, Wasserfal E, Kent S, et al. Increased serum interleukin-4 (IL-4) in IDDM: evidence for inheritance in multiplex families of a trait associated with protection from disease. Proc Natl Acad Sci USA. In press.
40. Keller RJ, Eisenbarth GS, Jackson RA. Insulin prophylaxis in individuals at high risk of Type 1 diabetes. Lancet. 1993;341:927-928.
41. Kolb H, Burkart V. Nicotinamide in type 1 diabetes - mechanism of action revisited. Diabetes Care. 1999;22:B16-B20.
42. Mandrup-Poulsen T, Riemers JI, Andersen HU, et al. Nicotinamide treatment in the prevention of insulin-dependent diabetes mellitus. Diabetes Metab Rev. 1993;9:295-309.
43. Pozilli P, Andreani D. The potential role of nicotinamide in the secondary prevention of IDDM. Diabetes. Metab Rev. 1993;9:219-230.
44. Elliott KB, Chase HP. Prevention or delay of type 1 (insulin dependent) diabetes mellitus in children using nicotinamide. Diabetologia. 1991;34: 362-365.
45. Rewers M, Bugawan TL, Norris JM, et al. Newborn screening for HLA markers associated with IDDM. Diabetes Autoimmunity Study in the Young (DAISY). Diabetologia. 1996;39:812-817.